PROF
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.
Profound Medical Corp. (PROF) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.
Quantitative Factor Evaluation • Updated
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | B- (2.9) | B- (3.1) | B (3.5) | B- (3.0) | C+ (2.6) | B- (3.0) |
| 2026-11-07 | B- (2.9) | B- (3.0) | B (3.5) | B- (3.0) | C+ (2.7) | B- (3.0) |
| 2026-10-31 | B- (2.9) | B- (3.0) | B+ (3.5) | C- (2.1) | C+ (2.7) | B- (2.9) |
| 2026-10-24 | B- (3.0) | B- (2.9) | B (3.5) | C- (1.9) | C+ (2.6) | C+ (2.8) |
Showing the last month only. Subscribe for the full factor score history.
For more — Subscribe